Skip to Content

New Treatments for Atopic Dermatitis to Come

Stephan Weidinger discusses the data on an OX40 ligand inhibitor that aims to target immune activation in atopic dermatitis (AD), which plays a crucial role in the proliferation and survival of antigen-specific T-cells. He also mentions other drugs in development, including one targeting OX40 receptors, IL-2 for stimulating T regulatory cells, and long-term safety and efficacy data for established biologics.

Stephan Weidinger

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top